Teva Pharmaceutical Industries has appointed Timothy R. Wright to its executive leadership team, as Head of Business Development, Strategy and Innovation.
In this new role, Wright will be responsible for identifying new sources of innovation. His appointment will be effective from 13 April, and he will report to President and CEO, Erez Vigodman.
‘The addition of Tim to our leadership team complements the strong management capabilities we have in Teva. He has a wealth of global experience which will serve us well as we look to create a new and exciting future for Teva,’ said Vigodman.
‘His significant experience across various aspects of healthcare and unique perspective will enable us to realise our full potential at this critical time of change in the pharmaceutical industry.’
Wright has almost 30 years of global experience in pharmaceuticals and biotech. Most recently, he was Director of the Drug Discovery and Development Institute at The Ohio State University Comprehensive Cancer Centre.
Prior to this, Wright was President of Covidien Pharmaceuticals from 2007–2010.
He was also CEO (Interim) & President, a member of the Board of Directors and Chief Operating Officer (2004–2007) at AAI Pharmaceuticals/Xanodyne. In addition he has held roles at Elan Pharmaceuticals and DuPont Merck Pharmaceutical Company.
